BETAWe are still building this site, so some contracts may be missing.Some contracts may be missing. Where our data comes from

Home › Browse › Not stated
Not stated GB FTS

Insulin pumps, continuous glucose monitoring products contributing to the delivery of hybrid closed loop pathways and associated products

SUPPLY CHAIN COORDINATION LIMITED. Combined from multiple notices.

Stage
Stage not stated
the buyer's notice does not place this at planning, tender or award. A named supplier below means it has been awarded.
Buyer
SUPPLY CHAIN COORDINATION LIMITED
Value
£3B
VAT basis not stated · GBP
End date
For subscribers only
First published
6 Feb 2026
last seen 10 Feb 2026

What the buyer published

NHS Supply Chain supports national diabetes services by enabling equitable access to advanced diabetes technologies, encouraging openness to innovation, and ensuring an appropriate balance between clinical outcomes, cybersecurity, interoperability, and value for money. This notice is published to inform the market and to invite suppliers to participate in preliminary market engagement in accordance with the Procurement Act 2023. NHS Supply Chain is exploring the potential establishment of an open framework agreement with a proposed duration of up to eight (8) years for the supply of insulin pumps, continuous glucose monitoring (CGM) devices, hybrid closed loop system components, and associated products and services. The proposed scope may include, but is not limited to, tethered insulin pumps, patch insulin pumps, continuous glucose monitoring devices, products contributing to the functionality of hybrid closed loop insulin delivery systems, consumables, and smart insulin pens. Precise quantities are unknown. It is anticipated that indicative expenditure in the first year may be in the region of £240,000,000 to £250,000,000 GBP (excluding VAT). This estimate is indicative only and may vary depending on the requirements of contracting authorities accessing the framework. The estimated total value over the potential eight year duration is approximately £3,000,000,000 GBP (excluding VAT). Any future framework agreement would support delivery of the NHS England Implementation Plan following the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA943 – Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes, published on 19 December 2023. Participation in this preliminary market engagement is voluntary and does not constitute a commitment by NHS Supply Chain to commence a procurement, to award a contract, or to include any participant in any future procurement process. Any future procurement will be conducted in accorda

The buyer published this contract more than once.

We combine all notices into one record, so it only appears here once.

NoticePublishedTypeStage
010763-2026 6 Feb 2026 planning
011652-2026 10 Feb 2026 other
View the original notice ↗